BiOptix to highlight new carbonic anhydrase data at IBC's Biopharmaceutical Development & Production Week

News provided by

Feb 27, 2013, 02:27 ET

BOULDER, Colo. and HUNTINGTON BEACH, Calif., Feb. 27, 2013 /PRNewswire/ -- BiOptix is highlighting new and compelling small molecule kinetics data from the new BiOptix 404pi at the IBC Biopharmaceutical Development & Production Week to be held from February 25 – March 1 2013 in Huntington Beach, CA. These new data sets continue to underscore the versatility of the BiOptix 404pi, an SPR instrument that is built for both protein-protein kinetics as well as protein-small molecule interactions.

"The carbonic anhydrase data from the BiOptix 404pi demonstrate the cornerstone of the BiOptix value proposition: high sensitivity, low noise and an ability to evaluate small molecule models," noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix. "Carbonic anhydrase analysis is the gold standard for evaluating SPR instrumentation and the BiOptix 404pi produces excellent data. BiOptix has designed and built—in the USA—a versatile SPR instrument that is available to the research community at a reasonable price."

Researchers are invited to learn more about the new BiOptix 404pi via the BiOptix Innovators Program—a unique to the industry "try before you buy" SPR instrumentation demo program. Additional details can be found at: http://www.bioptix.com/products/innovators-program

Surface Plasmon Resonance is an advanced and highly sensitive optical technology that measures refractive index changes on a sensor chip's gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.

About BiOptix

BiOptix Diagnostics Corporation is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction—with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com

SOURCE BiOptix Diagnostics Corporation